Nitric oxide donors and selective carbonic anhydrase inhibitors: A dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis

Molecules

Volumn 20, Issue 4, 2015, Pages 5667-5679

  Carradori, Simone ^a   Mollica, Adriano ^a   De Monte, Celeste ^b   Granese, Arianna ^b   Supuran, Claudiu T ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cancer; Dual pharmacological activity; Glaucoma; NO donors; Osteoporosis; Selective carbonic anhydrase inhibitors

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; NITRIC OXIDE;

GENETICS; GLAUCOMA; HUMAN; METABOLISM; NEOPLASMS; OSTEOPOROSIS; PATHOLOGY;

CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; GLAUCOMA; HUMANS; NEOPLASMS; NITRIC OXIDE; OSTEOPOROSIS;

EID: 84928799442     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20045667     Document Type: Review

References (34)

1. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today 2004, 9, 641-651.
2. Miller, M.R.; Megson, I.L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 2007, 151, 305-321.
3. Schmidt, H.H.H.W.; Walter, U. NO at Work. Cell 1994, 78, 919-925.
4. Gasco, A.; Fruttero, R.; Rolando, B. Focus on recent approaches for the development of new NO-donors. Mini-Rev. Med. Chem. 2005, 5, 217-229.
5. Serafim, R.A.M.; Primi, M.C.; Trossini, G.H.G.; Ferreira, E.I. Nitric oxide: State of the art in drug design. Curr. Med. Chem. 2012, 19, 386-405.
6. Burgaud, J.; Ongini, E.; Soldato, P.D. Nitric oxide-releasing drugs: A novel class of effective and safe therapeutic agents. Ann. N. Y. Acad. Sci. 2002, 962, 360-371.
7. Carpenter, A.W.; Schoenfisch, M.H. Nitric oxide release: Part II. Therapeutic applications. Chem. Soc. Rev. 2012, 41, 3742-3752.
8. Supuran, C.T. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzym. Inhib. Med. Chem. 2012, 27, 759-772.
9. Alp, C.; Maresca, A.; Alp, N.A.; Gültekin, M.S.; Ekinci, D.; Scozzafava, A.; Supuran, C.T. Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II. J. Enzym. Inhib. Med. Chem. 2013, 28, 294-298.
10. De Monte, C.; Carradori, S.; Secci, D.; D'Ascenzio, M.; Vullo, D.; Ceruso, M.; Supuran, C.T. Cyclic tertiary sulfamates: Selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives. Eur. J. Med. Chem. 2014, 84, 240-246.
11. D'Ascenzio, M.; Carradori, S.; Secci, D.; Vullo, D.; Ceruso, M.; Akdemir, A.; Supuran, C.T. Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: Synthesis, biological evaluation and molecular modelling studies. Bioorg. Med. Chem. 2014, 22, 3982-3988.
12. D'Ascenzio, M.; Carradori, S.; de Monte, C.; Secci, D.; Ceruso, M.; Supuran, C.T. Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII. Bioorg. Med. Chem. 2014, 22, 1821-1831.
13. D'Ambrosio, K.; Carradori, S.; Monti, S.M.; Secci, D.; Vullo, D.; Supuran, C.T.; de Simone, G. An out of the active site binding pocket for carbonic anhydrase inhibitors. Chem. Commun. 2015, 51, 302-305.
14. Gidaro, M.C.; Alcaro, F.; Carradori, S.; Costa, G.; Vullo, D.; Supuran, C.T.; Alcaro, S. Eriocitrin and apigenin as new carbonic anhydrase V A inhibitors, from a virtual screening of Calabrian natural products. Planta Med. 2015, doi:10.1055/s-0034-1396139.
15. Carradori, S.; de Monte, C.; D'Ascenzio, M.; Secci, D.; Celik, G.; Ceruso, M.; Vullo, D.; Scozzafava, A.; Supuran, C.T. Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII - A new scaffold for designing isoform-selective inhibitors. Bioorg. Med. Chem. Lett. 2013, 23, 6759-6763.
16. Alterio, V.; di Fiore, A.; D'Ambrosio, K.; Supuran, C.T.; de Simone, G. Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem. Rev. 2012, 112, 4421-4468.
17. Fabrizi, F.; Mincione, F.; Somma, T.; Scozzafava, A.; Galassi, F.; Masini, E.; Impagnatiello, F.; Supuran, C.T. A new approach to antiglaucoma drugs: Carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J. Enzym. Inhib. Med. Chem. 2012, 27, 138-147.
18. Goldstein, I.M.; Otswaldp, P.; Roth, S. Nitric oxide: A review of its role in retinal function and disease. Vis. Res. 1996, 36, 2979-2994.
19. Cavet, M.E.; Vittitow, J.L.; Impagnatiello, F.; Ongini, E.; Bastia, E. Nitric oxide (NO): An emerging target for the treatment of glaucoma. Investig. Ophtalmol. Vis. Sci. 2014, 55, 5005-5015.
20. Scozzafava, A.; Supuran, C.T. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell. Biochem. 2014, 75, 349-359.
21. Carta, F.; Supuran, C.T.; Scozzafava, A. Novel therapies for glaucoma: A patent review 2007-2011. Expert Opin. Ther. Pat. 2012, 22, 79-88.
22. Mincione, F.; Benedini, F.; Biondi, S.; Cecchi, A.; Temperini, C.; Formicola, G.; Pacileo, I.; Scozzafava, A.; Masini, E.; Supuran, C.T. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg. Med. Chem. Lett. 2011, 21, 3216-3221.
23. Steele, R.M.; Benedini, F.; Biondi, S.; Borghi, V.; Carzaniga, L.; Impagnatiello, F.; Miglietta, D.; Chong, W.K.M.; Rajapakse, R.; Cecchi, A.; et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg. Med. Chem. Lett. 2009, 19, 6565-6570.
24. Ekinci, D.; Çavdar, H.; Talaz, O.; Şentürk, M.; Supuran, C.T. NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II. Bioorg. Med. Chem. 2010, 18, 3559-3563.
25. Wistrand, P.J.; Lindqvist, A. Carbonic Anhydrase-From Biochemistry and Genetics to Physiology and Clinical Medicine; Botrè, F., Gros, G., Storey, B.T., Eds.; VCH: Weinhein, Germany, 1991; pp. 352-378.
26. Mincione, F.; Scozzafava, A.; Supuran, C.T. Antiglaucoma carbonic anhydrase inhibitors as ophthalomologic drugs. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C.T., Winum, J.Y., Eds.; Wiley: Hoboken, NJ, USA, 2009; pp. 139-154.
27. Pinard, M.A.; Boone, C.D.; Rife, B.D.; Supuran, C.T.; McKenna, R. Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases. Bioorg. Med. Chem. 2013, 21, 7210-7215.
28. Masini, E.; Carta, F.; Scozzafava, A.; Supuran, C.T. Antiglaucoma carbonic anhydrase inhibitors: A patent review. Expert Opin. Ther. Pat. 2013, 23, 705-716.
29. Coulter, J.A.; Mccarthy, H.O.; Xiang, J.; Roedl, W.; Wagner, E.; Robson, T.; Hirst, D.G. Nitric oxide - A novel therapeutic for cancer. Nitric Oxide 2008, 19, 192-198.
30. Reynolds, M.M.; Witzeling, S.D.; Damodaran, V.B.; Medeiros, T.N.; Knodle, R.D.; Edwards, M.A.; Lookian, P.P.; Brown, M.A. Applications for nitric oxide in halting proliferation of tumor cells. Biochem. Biophys. Res. Commun. 2013, 431, 647-651.
31. Cheng, H.; Wang, L.; Mollica, M., Re, A.T.; Wu, S.; Zuo, L. Nitric oxide in cancer metastasis. Cancer Lett. 2014, 353, 1-7.
32. Iyer, A.K.V.; Azad, N.; Wangb, L.; Rojanasakul, Y. Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide 2008, 19, 146-151.
33. Jamal, S.A.; Reid, L.S.; Hamilton, C.J. The effects of organic nitrates on osteoporosis: A systematic review. Osteoporos. Int. 2013, 24, 763-770.
34. Nakagawa, T.; Ohta, K.; Kubozono, K.; Ishida, Y.; Naruse, T.; Takechi, M.; Kamata, N. Zolendronate inhibits receptor activator of nuclear factor kappa-B ligand induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch. Oral. Biol. 2014, 60, 557-565.